1. 69P A real-world analysis of treatment-free survival for advanced melanoma patients treated with first-line immune checkpoint inhibitors. (December 2022) Authors: Gupta, M.; Stukalin, I.; Goutam, S.; Meyers, D.E.; Heng, D.Y.C.; Cheng, T.; Navani, V. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. Issue 1 (January 2020) Authors: Kushnir, I.; Kirk, L.; Mallick, R.; Kim, R.H.; Graham, G.E.; Breau, R.H.; Lattouf, J.-B.; Violette, P.D.; Pautler, S.E.; Care, M.; Kapoor, A.; Jewett, M.A.S.; Wood, L.; Tanguay, S.; Heng, D.Y.C.; Basappa, N.S.; So, A.; Pouliot, F.; Reaume, N.M. Journal: Clinical oncology Issue: Volume 32:Issue 1(2020) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017) Authors: Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.Y.C.; Aftab, D.T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S.; Hutson, T.E.; Choueiri, T.K. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗